Comparative Pharmacology
Head-to-head clinical analysis: INTRALIPID 20 versus LIPOSYN 10.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INTRALIPID 20 versus LIPOSYN 10.
INTRALIPID 20% vs LIPOSYN 10%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Intralipid 20% is a fat emulsion providing essential fatty acids and triglycerides. It serves as a source of calories and essential fatty acids. In parenteral nutrition, it prevents and treats essential fatty acid deficiency. In lipid rescue therapy for local anesthetic toxicity, it acts as a 'lipid sink' to sequester lipophilic drugs, and may also enhance mitochondrial fatty acid oxidation and improve cardiac contractility.
Intravenous fat emulsion provides a source of calories and essential fatty acids as a component of parenteral nutrition. The lipid particles are metabolized similarly to endogenous chylomicrons, undergoing hydrolysis by lipoprotein lipase to release free fatty acids, which are then used for energy or stored.
Intravenous infusion at a rate of 0.1 g fat/kg/hour, increasing to 0.5 g fat/kg/hour if tolerated. Maximum daily dose: 2.5 g fat/kg (50 mL/kg/day of 20% emulsion).
Intravenous infusion: 1-2 g/kg/day (10-20 mL/kg/day) as part of parenteral nutrition, not to exceed 2.5 g/kg/day. Infusion rate: initially 0.5-1 mL/min for 30 minutes, then increase to maximum 125 mL/hour if tolerated.
None Documented
None Documented
Terminal elimination half-life of lipid particles: approximately 30 minutes for chylomicron-like particles; triglycerides half-life ~15-30 minutes. Clinical context: rapid clearance by lipoprotein lipase.
Lipid emulsion particles: elimination half-life of 10-15 minutes; triglycerides: terminal half-life of 1-3 hours, reflecting redistribution and clearance from adipose tissue; clinical context: half-life is dose-dependent and prolonged in hypertriglyceridemia, hepatic impairment, or sepsis.
Renal: negligible. Biliary/fecal: >90% as component of lipid metabolism, excretion via bile and fecal elimination of lipid particles.
Renal: negligible; biliary: negligible; fecal: negligible; eliminated via peripheral lipoprotein lipase-mediated hydrolysis and subsequent metabolism of fatty acids, with CO2 production (~50-60%) and recycling into triglycerides and phospholipids; complete clearance from plasma within 24 hours of infusion cessation.
Category C
Category C
Intravenous Fat Emulsion
Intravenous Fat Emulsion